Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Coeptis Therapeutics Holdings Inc (COEPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: COEPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.12% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.59 | 52 Weeks Range 0.00 - 0.05 | Updated Date 02/25/2025 |
52 Weeks Range 0.00 - 0.05 | Updated Date 02/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -245.55% | Return on Equity (TTM) -1449.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 12704886 |
Shares Outstanding - | Shares Floating 12704886 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Coeptis Therapeutics Holdings Inc
Company Overview
History and Background
Coeptis Therapeutics Holdings, Inc. is a pharmaceutical company focusing on developing innovative therapies. Founded in 2013, it has shifted focus through strategic acquisitions and partnerships to develop its current portfolio of cancer therapeutics.
Core Business Areas
- Oncology: Coeptis develops therapies targeting various cancers. This involves researching, developing, and commercializing novel treatments.
- Exo-CR Immuno-Oncology Platform Technology: Coeptis develops advanced Immuno-Oncology platforms, that engineer exosomes for targeted and controlled delivery of various therapeutic modalities.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and commercialization. Details on specific individuals are readily available on their investor relations website.
Top Products and Market Share
Key Offerings
- CD38-GEAR-NK: A cell-based immunotherapy approach. Market share data is not publicly available. The competitors include companies that develop NK cell therapies.
- Exo-CR: Exo-CR delivers biologics for treating solid tumors. Market share data is unavailable as it is still in development. The competitors include companies in the exosome therapeutics field.
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and growing market driven by an aging population and increasing cancer incidence. It is highly competitive, with numerous companies developing new treatments.
Positioning
Coeptis Therapeutics is attempting to compete with novel therapies within the oncology space, focusing on immune-oncology. This niche could differentiate the company.
Total Addressable Market (TAM)
The global oncology market is expected to reach hundreds of billions of dollars. Coeptis is positioned within the developing cell and exosome therapeutic segment, with a goal to achieve a small portion of this large TAM.
Upturn SWOT Analysis
Strengths
- Innovative therapy platforms
- Focus on high-growth oncology market
- Strategic partnerships
Weaknesses
- Limited revenue
- Dependence on external funding
- Early-stage development pipeline
- High risk of clinical trial failure
Opportunities
- Successful clinical trials
- FDA approval and commercialization
- Expansion into new therapeutic areas
- Acquisition by a larger pharmaceutical company
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure of clinical trials
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- BMY
- GILD
- JNJ
Competitive Landscape
Coeptis faces an uphill battle against well-funded and established players. Its advantage lies in its novel technologies, but commercial success is uncertain.
Growth Trajectory and Initiatives
Historical Growth: Growth has been limited, with the company focusing on R&D rather than revenue generation.
Future Projections: Analyst projections suggest the potential for growth if clinical trials are successful. No financial targets available.
Recent Initiatives: Recent initiatives have focused on advancing its Exo-CR technology and clinical trials for its cancer therapeutics.
Summary
Coeptis Therapeutics is a developmental-stage pharmaceutical company focused on oncology, working with cutting-edge therapy platforms. The company's success hinges on the successful completion of its clinical trials and subsequent regulatory approval. It faces strong competition from large pharmaceutical firms. Coeptis has demonstrated limited revenue and substantial net losses and must continue to raise capital to operate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Third party market data from IBISWorld
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coeptis Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters Wexford, PA, United States | ||
IPO Launch date 2020-12-17 | Co-Founder, Chairman, CEO & Pres Mr. David Mehalick | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://coeptispharma.com |
Full time employees 4 | Website https://coeptispharma.com | ||
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.